However, the mechanisms of KLF5 action in vascular remodeling are still far from clear, and most approaches targeting KLF5 (e.g. miRNAs, antibodies, and inhibitors) in vascular disorder treatment are based on cell or animal experiments, while their clinical safety and effect are still obscure. The gene discussed is KLF5; the disease is vascular disorder.